Dual therapy activates immune defenses while damaging lung cancer DNA
A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while also stimulating the body's immune system to combat the disease. The research is published in the journal Cell Reports Medicine.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
